Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Brunner, TB.
Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?
Curr Oncol Rep. 2013; 15(2):162-9
Doi: 10.1007/s11912-012-0291-3
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Although neoadjuvant chemoradiotherapy has been tested for more than two decades and can be safely delivered to patients with non-metastatic pancreatic cancer, no randomised trials have been reported until now. Here we provide an overview of the first randomised trial in patients with potentially resectable cancer and of the latest developments in neoadjuvant therapy for this group of patients. It is necessary to continue to perform clinical trials in this field to accurately identify the effect on survival and quality of life in patients with potentially resectable, borderline resectable and unresectable pancreatic cancer. Aspects of imaging for restaging and clinical prognostic factors are also discussed given they will be useful instruments for future trials.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - therapeutic use
- Chemoradiotherapy, Adjuvant - methods
- Humans - administration & dosage
- Neoadjuvant Therapy - methods
- Pancreatic Neoplasms - therapy
- Randomized Controlled Trials as Topic - administration & dosage
- Find related publications in this database (Keywords)
- Pancreatic cancer
- Neoadjuvant chemoradiotherapy
- Potentially resectable
- Borderline resectable